Guideline recommendations and antimicrobial resistance : The need for a change by C. Elias et al.
 1Elias C, et al. BMJ Open 2017;7:e016264. doi:10.1136/bmjopen-2017-016264
Open Access 
AbstrAct
Objectives Antimicrobial resistance has become a 
global burden for which inappropriate antimicrobial use 
is an important contributing factor. Any decisions on the 
selection of antibiotics use should consider their effects on 
antimicrobial resistance. The objective of this study was to 
assess the extent to which antibiotic prescribing guidelines 
have considered resistance patterns when making 
recommendations for five highly prevalent infectious 
syndromes.
Design We used Medline searches complemented with 
extensive use of Web engine to identify guidelines on 
empirical treatment of community-acquired pneumonia, 
urinary tract infections, acute otitis media, rhinosinusitis 
and pharyngitis. We collected data on microbiology 
and resistance patterns and identified discrete 
pattern categories. We assessed the extent to which 
recommendations considered resistance, in addition to 
efficacy and safety, when recommending antibiotics.
results We identified 135 guidelines, which reported 
a total of 251 recommendations. Most (103/135, 79%) 
were from developed countries. Community-acquired 
pneumonia was the syndrome mostly represented (51, 
39%). In only 16 (6.4%) recommendations, selection of 
empirical antibiotic was discussed in relation to resistance 
and specific microbiological data. In a further 69 (27.5%) 
recommendations, references were made in relation 
to resistance, but the attempt was inconsistent. Across 
syndromes, 12 patterns of resistance with implications 
on recommendations were observed. 50% to 75% of 
recommendations did not attempt to set recommendation 
in the context of these patterns.
conclusion There is consistent evidence that guidelines 
on empirical antibiotic use did not routinely consider 
resistance in their recommendations. Decision-makers 
should analyse and report the extent of local resistance 
patterns to allow better decision-making.
bAckgrOunD
The appropriate use of antibiotics has 
become a worldwide priority. In 2000, glob-
ally it was estimated 54 billion standard units 
of antibiotics have been consumed, and this 
figure increased by 36% in the following 10 
years, creating the preconditions of a public 
health crisis.1 2 This problem is not confined 
to high and middle-income countries where 
antibiotics are considered as an undeniable 
right, but it is also accentuated in low-income 
countries where antibiotics are becoming 
part of a consumerist approach to healthcare; 
for example, the use of antibiotics is fourfold 
in India than in Scandinavian countries.3 4 
Inappropriate prescribing, over-the-counter 
sales of antibiotics and high consumption 
contributed to an increase in bacterial selec-
tion pressure. Time trend analyses have 
reported an increase in antimicrobial resis-
tance (AMR) including extended spectrum 
beta-lactamase, Gram-negative bacteria resis-
tant to carbapenems or plasmid-mediated 
colistin resistance.5 Such resistance patterns 
have been associated with negative outlooks 
on clinical and public health burden, 
including deaths, attributable to AMR.6
In the last 20 years, there has been an 
emphasis on the need to modify prescribers’ 
behaviours: guidelines emerged as an inter-
vention to support clinical decision-making 
through a consensual process based on 
evidence and reinforce collective action 
to tackle relevant disease problems.7 The 
adoption of guidelines targeting anti-
biotic prescribing, a medical behaviour 
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Research
strength and limitations of this study
 ► As part of the WHO Global Action Plan on Antimicrobial 
Resistance, this study is an innovative comparison 
of guidelines on the appropriate use of antibiotics 
based on resistance patterns across countries.
 ► Research was limited only to an electronic screening 
so printed versions of clinical practice guidelines 
may have been missed.
 ► Recommendations were arbitrarily hierarchised 
according to the influence of resistance data 
collected.
 ► Further research on the quality and relevance of 
specific recommendations based on resistance is 
needed identifying further obstacles to progress 
antimicrobial resistance and bringing them to light.
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characterised by scarce diligence, has been associated 
with large benefits, encompassing both improvement in 
mortality8 and in resistance.9 Conscious-scientific societies 
can contribute to control AMR by producing necessary, 
appropriate and specific recommendations to optimise 
the use of antibiotics and inviting health professionals to 
adhere to them.
We hypothesised that scientific societies and profes-
sional associations invested time and energies finalising 
guidelines to provide information on empirical antibiotic 
use. We assumed that these guidelines have at the core 
resistance threats and report information on country-spe-
cific resistance patterns, as these are essential information 
to guide the empirical choice of antibiotics. Therefore, 
we mapped guidelines targeting five common infectious 
conditions where empirical therapy prevails and evaluated 
what proportion of recommendations consider resistance 
patterns as a driver of the clinical decision-making, how 
resistance influences recommendations and whether 
resistance can be better incorporated.
MethODs
This study is part of a large comprehensive review of 
antibiotics that aims to revise the selection of antibi-
otics included in the 2017 WHO Model List of Essential 
Medicines, and is part of the 2015 Global Action Plan 
on Antimicrobial Resistance,10 a series of international 
actions to monitor and control antibiotics resistances.
Identification of guidelines
A guideline was eligible for inclusion if the publication 
type was a clinical practice guideline (CPG) consistent 
with the standard definition—‘statements that include 
recommendations intended to optimize patient care that 
are informed by a systematic review of evidence and an 
assessment of the benefits and harms of alternative care 
options’.11
A systematic search for CPGs of antibiotic therapy for 
five infectious disease syndromes—community-acquired 
pneumonia (CAP), urinary tract infections (UTIs), acute 
otitis media (AOM), rhinosinusitis (RHI) and pharyn-
gitis (PHA)—was conducted. We selected these diseases 
as a purposive sample of 23 syndromes considered in 
the comprehensive Essential Medicine List review. They 
represent the most prevalent infectious diseases world-
wide, a balanced case mix of benign and severe diseases 
and cover the spectrum of empirical antibiotic treatment 
choices.
To our knowledge, there is no single repository of CPGs 
on antibiotics. Therefore, to retrieve relevant CPGs, we 
first performed a Medline search using the following terms 
‘clinical practice guideline*’ or ‘guideline*’ in the title 
combined with the name of the syndrome as key words. 
For instance, looking at community-acquired pneumonia 
guidelines, we searched for ‘pneumonia’ or ‘commu-
nity acquired pneumonia’ or ‘respiratory tract infection’ 
or ‘lower respiratory tract infection’. Second, we used 
Google as the search engine to explore documents that 
are not reported in the medical literature but available on 
the internet assuming that a relevant number of guide-
lines would have been possibly published by scientific 
societies or governmental agencies and released on the 
internet but not captured by Medline or formal literature 
repositories. All searches were made using country-spe-
cific or local Google versions.12 So, for instance, French 
guidelines were searched on the local version of the 
Google page— Google. fr. For each website of a potential 
CPG issuer (eg, scientific society), one reviewer retrieved 
CPGs through an analysis of the official website. We finally 
searched the WHO Essential Medicines and Health Prod-
ucts Information Portal,13 an online repository of full-text 
publications on medicines and health products related 
to WHO priorities, other United Nations (UN) partners, 
global non-governmental organisations, development 
agencies and their partners, countries and academics. 
Resources within the portal were filtered with the help of 
the WHO information specialist in charge of organising 
the portal information.
Our searches were conducted during the period June–
July 2016. No date, language or age restrictions were 
applied.
Systematic reviews, meta-analyses as well as consensus 
conferences were excluded. Duplicated and guidelines 
superseded by more recent version were also removed.
Information sought for each guideline
For each included guideline, we sought general infor-
mation about the country of origin, its income and 
geographical place according to the WHO regions, infec-
tious syndrome, year of publication, target population, 
promoting institution and financial support.
Influence of resistance patterns over recommendations
To be included in the descriptive analysis, a CPG had to 
provide recommendations on the empirical use of anti-
biotic treatments for at least one syndrome. We used the 
standard definition of recommendation of the WHO. That 
implies a choice between different interventions—antibi-
otics in the actual study—that have an impact on health 
and that have implications for the use of resources.14
It is important to notice that each CPG can present 
recommendations across multiple syndromes. We 
considered each recommendation on antibiotic use as a 
potential opportunity to incorporate resistance pattern 
information (ie, desirable criterion). We assumed that 
patterns should be included in any recommendations 
about optimal use of antibiotics, the most conservative 
scenario being that a recommendation clearly excludes 
relevant resistance, and then recommends preferred 
antibiotic choice with a curative intent, considering 
avoidance of further development or spread of resistance. 
An example is recommending first-line antibiotic therapy 
amoxicillin or amoxicillin with clavulanate (alternative) 
for otitis media. Complex scenarios would consider, for 
instance, the recommendation of alternative antibiotics 
based on resistance thresholds.
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Table 1 Hierarchy of the recommendations
Level of satisfaction 
of recommendations Desirable criterion Illustration
Satisfactory Empiric antibiotic 
recommendation was supported 
by country-specific resistance 
patterns.
Management for uncomplicated cystitis in women in Sweden 
listed recommendations for preferred antibiotics. For instance, 
nitrofurantoin was a preferred option as a first-line treatment 
because of low resistance rates in a community setting, whereas 
fluoroquinolones were not indicated in this syndrome due to 
rapidly increasing resistance development.30
American recommendations for bacterial rhinosinusitis recommend 
high-dose amoxicillin as a preferred option over standard-dose 
amoxicillin primarily to cover and control PRSP.17
Partial satisfactory Empiric antibiotic 
recommendation was supported 
by inconsistent resistance 
patterns.
Filipino recommendations for mild CAP recommended the use 
of a beta-lactam with a beta-lactamase inhibitor without any 
justification on resistance. However, macrolides were considered 
as an alternative treatment because of a high threshold of 
resistance (20% resistance rate) among population.31
Unsatisfactory Empirical antibiotic 
recommendation did not support 
any resistance patterns or was 
not justified by country-specific 
resistance patterns.
Beta-lactams as well as macrolides were recommended for the 
management of pharyngitis in Namibia without any specification 
about microbiology or resistance.32
CAP, community-acquired pneumonia; PRSP, penicillin resistant Streptococcus pneumoniae.
Recommendations were classified according to the 
influence of epidemiological and resistance patterns 
data on recommendations in three ordinal catego-
ries: satisfactory, partial satisfactory and unsatisfactory 
(table 1). They were considered as satisfactory if they 
provided a list of empirical antibiotics modulated by 
complete and country-level collected data on microbi-
ological and resistance patterns. In fact, we arbitrarily 
postulated that recommendations about optimal anti-
biotic use should consider country-specific resistance 
patterns as a key driver of the selection of antibiotic. 
Resistance patterns had to be consistently reported 
across recommendations targeting antibiotic use for a 
syndrome. Partially satisfactory recommendations had 
some but not all of the resistance pattern information 
or used this information inconsistently across recom-
mendations. Lastly, recommendations were classified as 
unsatisfactory when: they did not use epidemiological 
and resistance data to justify antibiotic selection, recom-
mendations were delinked from resistance patterns or 
these were not country specific.
For each guideline, one reviewer retrieved information 
through an analysis of the document. The same reviewer 
also classified the satisfactory level based on the complete-
ness of resistance patterns information. Different patterns 
were collegially discussed and doubts were resolved .
For each infectious syndrome, we identified discrete 
characteristics of resistance with implications on recom-
mendations. In other words, if a recommendation 
contained data on resistance, it could generate guidance 
based on such resistance patterns, suggesting appro-
priate or inappropriate antibiotics (eg, using a specific 
antibiotic such as amoxicillin-clavulanate in case of risk 
of bacterial strains producing beta-lactamase in mild 
CAP). We then calculated how many recommendations 
failed to consider discrete patterns, reporting median 
and IQR as measures of distribution.
results
We retrieved 148 CPGs: 21 (14%) from Medline, 97 (66%) 
from websites of specialty societies and 30 (20%) from the 
WHO Essential Medicines and Health Products Informa-
tion Portal. Of these CPGs, 135 (91%) met our inclusion 
criteria and were described in details, and provided suffi-
cient information for qualitative evaluation. Thirteen 
guidelines were excluded because no recommendation 
on empirical treatment was made or were duplicates or 
out-of-validity guidelines (figure 1).
General characteristics of the guidelines are 
summarised in table 2. Among the 194 UN member 
states, 70 (36%) provided guidelines of at least one 
of the five syndromes. The majority (106, 79%) of the 
CPGs arose from high and upper middle-income coun-
tries, whereas lower middle and low-income countries 
contributed marginally (28, 21%). European Regional 
Office and Pan American Regional Office were the 
two most represented WHO regions, originating 44 
(33%) and 39 (29%) CPGs, respectively. Among the 
five infectious syndromes studied, CAP’s treatment was 
the top-ranked syndrome in the agenda (51, 39%), 
followed by UTI (42, 31%). Half of the CPGs were 
published between 2011 and 2016. Figure 2 shows the 
geographical distribution of guidelines across the 194 
UN member states.
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Figure 1 Flow chart of clinical practice guideline. AB, antibiotic.
A total of 251 recommendations were identified: these 
subgrouped by syndromes will be considered the denom-
inators in the following analyses.
Compliance with our desirable criteria is presented in 
table 3. Only a minority of the recommendations—16 
(6.4%)—was classified as satisfactory (ie, including or 
mentioning resistance), whereas 69 (27.5%) and 166 
(66.1%) recommendations partially or totally omitted 
data on microbiological resistance, respectively. 
Guidelines that incorporated resistance on all recom-
mendations originated from France,15 Sweden16 and 
the USA.17 18
Descriptive analysis of the resistance patterns is shown 
in table 4. Of the 12 discrete patterns how resistance 
may influence recommendations, 10 patterns were iden-
tified for CAP, 6 for UTI, 7 for rhinosinusitis and acute 
otitis media and finally 4 for pharyngitis. Looking at the 
distribution of resistance into recommendations, 50% to 
75% of recommendations failed to mention resistance 
patterns in the antibiotic guidance when these patterns 
might have had an impact.
For CAP, the risk for atypical pathogens was addressed 
in 26% of the recommendations. Multidrug resis-
tance concerns, however, were covered only in 1.4% of 
recommendations. Resistance patterns in UTI recom-
mendations ranged from two to five, and nine (14.3%) 
UTI recommendations described alternative antibiotics 
based on resistance threshold.
No satisfactory recommendation was identified for the 
management of pharyngitis. Resistance is rare in the most 
common pathogens for bacterial pharyngitis, thus, only 
one resistance pattern by pharyngitis’ recommendations 
was found.
For all syndromes antibiotics used as an alternative were 
often mentioned. Fluoroquinolones appeared to be the 
most frequent alternative antibiotic in CAP (11%) and 
UTIs (12.7%) (see online supplementary tables 1 and 2). 
Detailed alternative antibiotics and resistance patterns 
in acute otitis media, rhinosinusitis and pharyngitis are 
referenced in online supplementary tables 3, 4 and 5 .
DIscussIOn
In view of the postantibiotic era and the global burden 
of antibiotic resistance worldwide, it is important that 
recommendations consider (in)appropriate antibiotics 
when there is an opportunity to reduce resistance. This 
review found an important gap in antibiotics guidelines: 
resistance patterns were not considered by two-thirds of 
recommendations for five highly prevalent infectious 
syndromes. Moreover, of the 251 recommendations, 
fewer than 1 in 10 consistently reported data on their 
country-specific resistance patterns. The recommen-
dation would serve better the medical community if a 
specific antibiotic is preferred over the others, with the 
aim of providing appropriate coverage and minimising 
spread and development of resistance. If resistance is 
not considered in guideline development, it is unlikely 
to be considered downstream. These data imply that 
significant changes are needed to the way resistance 
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  HIC 78 58
  UMIC 28 21
  LMIC 17 13
  LIC 11 8
WHO region*
  AFRO 23 17
  EMRO 8 6
  EURO 44 33
  PAHO 39 29
  SEARO 3 3
  WPRO 16 12
Syndromes
  Community acquired pneumonia 51 39
  Urinary tract infections 42 31
  Acute otitis media 16 12
  Rhinosinusitis 14 10
  Pharyngitis 12 8
*Total of 133, European Union was not part of a WHO region or the 
World Bank classification.33
AFRO, African Regional Office; CPG, clinical practice guidelines; 
EMRO, Eastern Mediterranean Regional Office; EURO, European 
Regional Office; HIC, high-income country; LIC, low-income 
country; LMIC, lower middle-income country; PAHO, Pan American 
Regional Office; SEARO, South East Asia Regional Office; UMIC, 
upper middle-income country.
data are considered in recommendations for antibi-
otics.
Given the scarce attention to resistance, it is not 
surprising that evidence of substantial inappropriate or 
overuse of non-first-line antibiotics for most common 
conditions is prevalent in the medical literature. For 
instance, data from the USA indicate that the problem 
of inappropriate antibiotic prescribing includes not 
only prescriptions that are unnecessary altogether, 
but also inappropriate selection of agents: physicians 
prescribed inappropriate antibiotics in about 30% to 
50% of ambulatory adult consultations with suspected 
common infectious diseases.19 20 However, when guid-
ance is provided, evidence shows a more conscious use 
of antibiotics.21 Since large areas of the world lack the 
infrastructure to collect resistance data, countries in need 
should be supported through international projects such 
as ReAct22 or Ecumenical Pharmacy Network.23 Guide-
lines certainly deserve attention, but implementation and 
quality improvement interventions are also important. 
Indeed, education and incentives that facilitate anti-
biotic optimal prescription should also be sustained by 
adequate policies.
In the move towards better management of resistance, 
there is room for better standardisation of approaches 
to include resistance on recommendations and better 
reporting of resistance data. Panels should scrutinise 
country-specific resistance data when considering anti-
biotic recommendations and should report the data, 
including important time trends. The quality of guide-
lines is closely intertwined with the quality of reporting. 
It is possible that guidelines took resistance patterns 
into consideration in their recommendations without 
mentioning it. Lack of details on how recommendations 
were developed leads users to assume that the quality 
was inadequate, unless information to the contrary is 
provided.24 This is often justified because faulty reporting 
generally reflects faulty methods.25
Although some findings are worrisome, other look more 
positive. One-third of countries had at least one guideline 
on antibiotic use: even in the absence of published data, 
this number suggests that the guideline panels invested 
a remarkable amount of energy in this field. Fourteen 
countries produced more than two guidelines for at least 
one syndrome, raising concerns for duplication of efforts. 
The more prolific country, Spain, had a production of 13 
documents, likely to generate redundancy and confusion. 
Most guidelines were from high-income countries, with 
low- and lower middle-income countries providing only 
21%. Weak healthcare systems, including inadequate 
infrastructures for resistance collection, may justify the 
absence of epidemiological and resistance data in these 
countries.
Resistance patterns are highly heterogeneous: patterns 
in upper respiratory tract infections and UTIs are limited 
in comparison with CAPs. In the latter, antibiotics and 
resistance may play a substantial role avoiding an evolu-
tion into life-threatening diseases. Paucity of resistance 
data in upper respiratory tract infections can be explained 
by the high probability of a viral aetiology and a benign 
disease decourse. Antibiotics are not recommended as 
treatment by many scientific societies: the National Insti-
tute of Health and Care Excellence guidelines (UK) did 
not include any antibiotic therapy in their guidance for 
these three syndromes.26 This approach converges with 
the concept of wait-and-see prescription to reduce unnec-
essary antibiotics use, which demonstrated to be efficient 
in the treatment of acute otitis media in children.27
National and international recommendations should 
be accompanied by facility-specific antibiotic recommen-
dations, particularly for common syndromes. Among 
the others, surgical prophylaxis has an important role 
as target of local stewardship programmes. Most guide-
lines recommend a maximum postoperative duration of 
surgical antibiotic prophylaxis of 24 hours, but increasing 
evidence shows that using only a single preoperative dose 
(and possible additional intraoperative doses according 
to the duration of the operation) might be equally effec-
tive.28 Prophylaxis use should be risk adjusted according 
to surgical procedures to ensure that harms in terms 
of bacterial resistance do not outweigh the benefits. 
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Figure 2 Geographical distribution of clinical practice guidelines (n=135).















Satisfactory 4 (5.5) 5 (7.9) 3 (7.1) 4 (10.2) 0 (0) 16 (6.4)
Partial satisfactory 31 (42.5) 11 (17.4) 11 (26.2) 6 (15.4) 10 (29.4) 69 (27.5)
Unsatisfactory 38 (52.0) 47 (74.6) 28 (66.7) 29 (74.4) 24 (70.6) 166 (66.1)
Total 73 63 42 39 34 251
AOM, acute otitis media; CAP, community acquired pneumonia, PH, pharyngitis; RH, rhinosinusitis; UTI, urinary tract infection.
Implementation of a monitored antibiotic policies results 
in lower total antibiotic consumption, reduced antibiotic 
resistance and reduced costs without increasing the risk 
of postoperative infections.29
We recognise that our study can provide nothing more 
than a snapshot of the current state of the recommen-
dations related to one dimension, antibiotic resistance. 
Comprehensive user-centred evaluations of the overall 
quality of guideline are needed. It was not our aim to 
assess whether recommendations have improved or 
worsened over time. Rather we sought to assess whether 
a problem existed at the time of our study. We did not 
investigate if recommendations on discrete resistance 
patterns were correct, or supported by evidence. The 
relevance of resistance patterns was not weighted. We 
accepted study authors’ guidance on discrete patterns at 
face value, without further evaluating the quality of the 
recommendation. We adopted a non-validated arbitrary 
ordinal scale. Searches were done by a single researcher. 
We did not consider paper-based guidelines, which might 
be still prevalent in some contexts. Further research on 
the quality and relevance of specific recommendations 
based on resistance is needed identifying further obsta-
cles to progress AMR and bringing them to light.
cOnclusIOn
Our findings revealed that guidelines on empirical use 
of antibiotics do not provide meaningful information on 
resistance patterns and interpretation by decision-makers 
is difficult because—as a principle—local resistance 
patterns should always be considered with empirical anti-
biotic choices. In appraising the evidence for antibiotic 
use guideline, developers should be aware of the breadth 
and depth of overarching resistance issues. Awareness 
and understanding of AMR through surveillance and 
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Recommendations considering resistance patterns
  Antibiotic used as an alternative because of high 
resistance rate
14 (19.2) 9 (14.3) 5 (11.9) 3 (7.7) 1 (2.9)
  Antibiotic not indicated because of high resistance rate 2 (2.7) 6 (9.5) 1 (2.4) 3 (7.7) 5 (14.7)
  Resistance risk 12 (16.4) 7 (11.1) 4 (9.5) 3 (7.7) _
  Resistance threshold _ 9 (14.3) _ 2 (5.1) 2 (5.9)
  Resistance AB _ 5 (7.9%) _ _ _
  Resistance dosage 8 (11.0) _ 7 (16.7) 8 (20.5) _
  Atypical pathogens 19 (26.0) _ _ _ 1 (2.9)
  MRSA risk 7 (9.6) _ _ _ _
  MDR risk 1 (1.4) 5 (7.9) 1 (2.4) _ _
  PRSP risk 6 (8.2) _ 6 (14.3) 5 (12.8) _
  Pseudomonas risk 14 (19.2) _ _ _ _
  Beta-lactamase risk 8 (11.0) _ 11 (26.2) 7 (17.9) _
Discrete resistance patterns mentioned in 
recommendations





































AOM, acute otitis media; Atypical pathogens, risk of atypical pathogens; CAP, community acquired pneumonia; MDR risk, risk of multidrug 
resistant strains; MRSA risk, risk of meticillin-resistant Staphylococcus aureus; PHA, pharyngitis; PRSP risk, risk of penicillin resistant 
Streptococcus pneumonia; Pseudomonas risk, risk of Pseudomonas aeruginosa; Resistance AB, antibiotic used if first-line AB is resistant; 
Resistance dosage, antibiotic used at high dosage if there is a risk of resistant strains; Resistance risk, antibiotic used only if there is a risk of 
increasing resistance (eg, recent use of critical AB during past months); Resistance threshold, antibiotic used only under a certain threshold of 
resistance; RHI, rhinosinusitis; UTI, urinary tract infection; beta-lactamase risk, risk of strains producing beta-lactamase.
research are pillars of the WHO Global Action Plan on 
Antimicrobial Resistance. These results can be used 
by global initiatives such as the UN General Assembly 
High-Level Meeting on Antimicrobial Resistance and the 
Conscience of Antimicrobial Resistance Accountability 
Alliance to monitor progress.
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